FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPRO	VAL							
	OMB Number:	3235-0287							
l	Estimated average burden								
l	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  KAKKIS EMIL D							2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Ultragenyx Pharmaceutical Inc.</u> [ RARE ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner				
(Last) (First) (Middle) C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT						3. Date of Earliest Transaction (Month/Day/Year) 08/28/2017								X Officer (give title Other (specify below)  President & CEO					
(Street) NOVATO CA 94949					4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person					
(St													<u> </u>						
1. Title of Security (Instr. 3) 2. Trai			2. Transact Date	nsaction		2A. Deemed Execution Date,		3. Transa	ction	4. Securities Acquired (A)		or	5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) o (D)	r Pri	ce	Transaction	action(s)		(Instr. 4)		
Common Stock				08/28/2017				P		5,853	A	\$	52.4 <sup>(1)</sup>	2,5	558,094	I	By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009		
Common Stock 08/				2017				P		1,647	A	\$5	\$52.96 <sup>(2)</sup>		559,741	I	By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009		
Common Stock													430,569		D				
	Ta	able II -												wned					
Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any		on Date,	4. Transaction Code (Instr.		n of		6. Date Exerc Expiration Da		te	7. Title and Amount of Securities Underlying Derivative		Deriv Secu (Inst	ivative description of the control o	derivative Securities Beneficially Owned Following Reported	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
		Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	or Numb of	er								
	(Figrade National Content of Exercise Price of Derivative Security (Instance of Exercise Price of Derivative	(First) (CRAGENYX PHARMACE ERONI COURT  CA (State) (Court Table Security (Instr. 3)  Stock  Stock  Table Security (Instr. 3)  Stock  Table Security (Instr. 3)	(First) (Middle) CRAGENYX PHARMACEUTICAL ERONI COURT  CA 94949  (State) (Zip)  Table I - No Security (Instr. 3)  Stock  Table II -  2. Conversion or Exercise Price of Derivative Security  (Month/Day/Year)  A Dee Execution of Derivative Security  (Month/Day/Year)	(First) (Middle)  (RAGENYX PHARMACEUTICAL INC.  (State) (Zip)  Table I - Non-Derivative (Month/Day)  Stock  Table II - Derivatire (e.g., put (Month/Day)Year)  2. Transaction Date (Month/Day)Year)  A Demend Execution Date, if any (Month/Day)Year)  [2.	Conversion or Exercise Price of Derivative Security   Code	Conversion of Exercise Price of Derivative Security (Month/Day/Year)   Stock   Stock	Stock   Stoc	(First) (Middle) RAGENYX PHARMACEUTICAL INC. RRONI COURT  Table I - Non-Derivative Securities Act (Month/Day/Year)  Stock  Table I - Derivative Securities Acquee, g., puts, calls, warrants, and or Security  Stock  Table II - Derivative Securities Acquee, g., puts, calls, warrants, and or Security  (Month/Day/Year)  2. Transaction Date if any (Month/Day/Year)  Stock  Table II - Derivative Securities Acquee, g., puts, calls, warrants, and or Security  (E.g., puts, calls, warrants, and Security (Month/Day/Year)  Acquired Security  (Month/Day/Year)  Acquired Securities Acqueed Execution Date, if any (Month/Day/Year)  (Month/Day/Year)  Code (Instr. 3, 4 and 5)  Code V (A) (D)	Caronersion   Caronersion	Stock   Stoc	Code   Name   Code   Name	Stock   Stoc	Carrier   Carr	Check   Client   Conversion   Conversion	Stock   Ultragenyx Pharmaceutical Inc.   RARE   Checked and X   Stock   OB/28/2017   Stock	Concession   Con	Check at application   Content   C		

- 1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$51.89 to \$52.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- 2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$52.90 to \$52.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

## Remarks:

/s/ Ruben A. Garcia, attorneyin-fact

08/29/2017

\*\* Signature of Reporting Person

Date

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.